Cambridge, MA, January 12, 2001—BioTrove, Inc., formerly Advanced Instrumentation
Systems, Inc., announced today it has entered into a collaborative research
agreement with Pfizer
Inc. (NYSE:PFE) for the development of BioTrove's ultra-high throughput
screening technology for use in Pfizer's research facilities.
Under the terms of the two-year agreement, BioTrove will develop a ultra-high
throughput screening platform integrating proprietary nanoscale liquid
handling technologies to be purchased by Pfizer for use by Pfizer research
sites.
"BioTrove is extremely pleased to have entered into this relationship
with Pfizer," said Colin Brenan, Ph.D., Chief Executive Officer and co-founder
of BioTrove, Inc. "Pfizer is an innovative research-based company that
has recognized the value of technological innovation in accelerating the
drug discovery process. BioTrove has created advanced technology purposely
designed to speed the analysis of drug compounds in nanoliter volume assays
and at high rates. We believe that BioTrove's system will be of great
benefit to Pfizer and other companies to accelerate drug development and
design."
About BioTrove
BioTrove is a privately-held company providing innovative technological
solutions to the life science industry. Their proprietary drug discovery
technology platforms are designed to substantially increase the efficiency
of the entire pre-clinical drug discovery process from combinatorial chemistry,
target identification, through high-performance screening and profiling,
to ADME/Tox studies.
For more information contact:
Colin Brenan, C.E.O.
Robert Hess, V.P. Business Development
|
